USP 795, 797, and 800: A Practical Overview for 503A Pharmacies

If you compound medications in a 503A pharmacy, you operate under at least two USP chapters — and possibly all three. USP 795 governs non-sterile compounding. USP 797 governs sterile compounding. USP 800 governs hazardous drug handling. Understanding which chapters apply to your operation, how their requirements interact, and where pharmacies most commonly fall short is the foundation of a functional compliance program.

USP 795: Non-Sterile Compounding

USP Chapter 795 applies to any pharmacy that prepares non-sterile compounded preparations — creams, ointments, oral solutions, suppositories, troches, and similar dosage forms. If your 503A pharmacy does any non-sterile compounding at all, USP 795 applies to you.

The chapter's core requirements cover:

• Facility and equipment: Designated compounding areas, appropriate equipment for the dosage forms prepared, cleaning and maintenance records
• Personnel training: Training requirements for everyone involved in compounding, with documentation
• Formulation and compounding records: Master formulation records (MFRs) and compounding records (CRs) for every preparation
• Beyond-use dating: BUD limits assigned by water activity (a_w) of the preparation. In the absence of stability data, Table 4 sets the ceilings: nonpreserved aqueous (a_w ≥ 0.60) is 14 days refrigerated; preserved aqueous is 35 days; nonaqueous oral liquids (a_w < 0.60) is 90 days; other nonaqueous dosage forms is 180 days. Stability data can extend a BUD up to 180 days maximum.
• Quality control: In-process and final checks, appearance and weight verification

The 2023 revision to USP 795 introduced updated BUD tables and enhanced quality control requirements. If your non-sterile SOPs were written against the previous version of the chapter, they need review.

What 503A pharmacies often miss: The requirement for written master formulation records. Many smaller non-sterile operations have informal "recipes" rather than formal MFRs. This is a common inspection citation — and an easy one to fix with the right documentation infrastructure.

USP 797: Sterile Compounding

USP Chapter 797 applies to any pharmacy that prepares sterile compounded preparations — injections, ophthalmic preparations, irrigation solutions, inhalation solutions, and other dosage forms intended to be free of microorganisms and particulate matter.

The chapter is significantly more demanding than USP 795, reflecting the higher patient risk associated with sterile preparations:

Facilities: Cleanrooms must meet ISO classification requirements — typically an ISO 5 primary engineering control (PEC) within an ISO 7 buffer room, with an ISO 8 ante-area. The physical facility itself must be certified and recertified on defined intervals.

Environmental monitoring: An ongoing program of surface and air sampling, with defined alert and action levels, corrective action procedures, and trending requirements.

Personnel: Garbing competency must be demonstrated through direct observation, gloved fingertip testing, and media fills. Initial qualification and ongoing re-qualification are both required.

Beyond-use dating: Under the revised chapter, BUDs are tied to the CSP's category classification — Category 1, Category 2, or Category 3 — and to the process used to prepare it. Category 1 caps at 12 hours CRT / 24 hours refrigerated with no sterility testing required, and may be compounded in an unclassified Segregated Compounding Area (SCA). Category 2 requires a full ISO 5/7/8 cleanroom suite and permits extended BUDs per Table 13, where the allowable row depends on whether starting components are sterile, whether the CSP is aseptically processed or terminally sterilized, and whether a passing sterility test was performed. Category 3 unlocks the longest allowable BUDs in the chapter — up to 180 days frozen for terminally sterilized preparations — in exchange for the most stringent controls, including sterility testing on every batch, weekly sporicidal disinfection, and quarterly (every 3 months) personnel competency requalification.

SOPs: A complete library of written SOPs covering every aspect of sterile compounding operations — cleaning, disinfection, garbing, compounding processes, equipment maintenance, environmental monitoring, and more.

What 503A pharmacies often miss: Personnel competency records are the most common inspection gap for sterile operations. Specifically: gloved fingertip testing records, media fill documentation at required intervals, and garbing competency sign-offs via direct observation. "She's been doing this for ten years" is not a competency record.

USP 800: Hazardous Drugs

USP Chapter 800 is the chapter that catches the most pharmacies off guard — because it applies to every pharmacy that handles hazardous drugs, regardless of whether the pharmacy does sterile or non-sterile compounding.

If your 503A pharmacy receives, stores, prepares, or dispenses any drug on the NIOSH List of Antineoplastic and Other Hazardous Drugs, USP 800 applies to you. This includes many hormone preparations — a category that is extremely common in 503A compounding.

Key USP 800 requirements:

• Hazardous drug list: You must maintain a list of HDs you handle that includes any items on the current NIOSH list, and review it at least every 12 months. An optional assessment of risk may be performed for certain final dosage forms (e.g., intact tablets or capsules dispensed without further manipulation) to justify alternative containment strategies — but this option does not apply to HD APIs or to antineoplastic HDs requiring manipulation, which must follow all containment requirements in the chapter.
• Facilities: HD compounding — both sterile and non-sterile — must be performed inside a containment primary engineering control (C-PEC), which is itself placed inside a containment secondary engineering control (C-SEC). For non-sterile HD compounding, the C-SEC must be externally vented, maintain at least 12 ACPH, and hold a negative pressure of 0.01–0.03 inches of water column relative to adjacent areas. For sterile HD compounding, the C-SEC is either an ISO Class 7 buffer room with an ISO Class 7 ante-room (preferred, 30 ACPH) or an unclassified containment segregated compounding area (C-SCA, 12 ACPH) with the BUD limits 〈797〉 assigns to a segregated compounding area. A C-PEC is not required when manipulations are limited to handling final dosage forms (e.g., counting or repackaging of intact tablets or capsules) that do not produce particles, aerosols, or gases.
• Personal protective equipment (PPE): Defined PPE requirements for receipt, storage, transport, compounding, administration, deactivation/cleaning, spill control, and waste disposal — including two pairs of ASTM D6978 chemotherapy gloves and a disposable, back-closing, permeation-resistant gown.
• Deactivation, decontamination, cleaning, and disinfecting: Written procedures and defined agents for each of the four steps (each step is distinct, not interchangeable).
• Spill procedures: Written spill response procedures, spill kits accessible in all areas where HDs are handled, and trained personnel to manage spills of the size they may encounter.
• Medical surveillance and reproductive risk: Personnel of reproductive capability must confirm in writing that they understand the risks of handling HDs, and the entity must have a medical surveillance program in place where feasible.

How the Three Chapters Overlap

Understanding which chapters apply is one thing. Understanding how they interact in a real compounding operation is where it gets complicated.

Non-sterile pharmacy compounding non-hazardous drugs: USP 795 only. This is the simplest scenario — SOPs, MFRs, compounding records, BUD assignment, and quality control under a single chapter.

Non-sterile pharmacy compounding hazardous drugs: USP 795 + USP 800. The 795 framework applies to the compounding process; USP 800 adds the containment, PPE, and handling requirements specific to the hazardous nature of the drug. Non-sterile HD compounders often underestimate the 800 requirements because they do not have a cleanroom — but the containment and PPE requirements still apply.

Sterile pharmacy compounding non-hazardous drugs: USP 797 only. The full 797 framework — cleanroom certification, EM, garbing competency, extended BUD documentation.

Sterile pharmacy compounding hazardous drugs: USP 795 (if any non-sterile), USP 797, and USP 800. This is the most demanding scenario. The cleanroom must meet 797 requirements and the containment requirements of 800 simultaneously. Negative-pressure requirements for HDs must be reconciled with ISO classification requirements for sterile compounding. Garbing must address both 797 and 800 PPE requirements.

State Adoption: Not All States Are on the Same Chapter

Here is a complexity that catches even well-intentioned pharmacies: USP chapter adoption is not uniform across state Boards of Pharmacy.

USP publishes chapter revisions. State Boards adopt those chapters — by rule, by reference, or through formal rulemaking — on their own timelines. The revised USP 795 became official on November 1, 2023; the revised USP 797 became official on February 1, 2025 after an appeals-driven delay from its originally announced November 1, 2023 date. Some states adopted these chapters on their respective official dates. Others are still enforcing the previous versions, or have phased adoption schedules tied to specific rulemaking proceedings. A handful have not formally adopted USP 800 at all, though many inspectors apply its principles informally.

This means your compliance obligation is defined by what your state has adopted, not necessarily what the current USP publication says. When chapters are revised and your state has not yet adopted the new version, you may need to maintain compliance with both — the old version for regulatory purposes and awareness of the new version for anticipated future requirements.

Know your state's adoption status. If you are unsure, your State Board of Pharmacy website should have the relevant rules — or call and ask directly.

Building a Compliance Program That Covers All Three

The practical challenge for 503A pharmacies is not understanding what each chapter requires in isolation — it is building a compliance program that covers all applicable requirements simultaneously, without duplication or gaps.

A few principles that simplify this:

One SOP library, not three. Your SOPs should be organized by function, not by chapter. Your garbing SOP addresses garbing requirements whether those come from 797 or 800. Your cleaning SOP addresses the requirements of both chapters in one document. Writing separate "797 SOPs" and "800 SOPs" for the same process creates duplication, inconsistency, and maintenance burden.

One attestation workflow. Staff should be completing a single, role-appropriate set of competency activities that cover the requirements of all applicable chapters. Separate training curricula for each chapter lead to gaps.

One obligation calendar. Every required periodic activity — EM sampling, equipment certification, SOP review, competency re-qualification — should live in a single calendar so nothing falls through the cracks between chapters.

References

All compliance content in this article is sourced directly from the official text of the USP chapters. Specific section and table references:

USP 〈795〉 Pharmaceutical Compounding — Nonsterile Preparations (official as of November 1, 2023)

• §1.1 Scope — CNSP dosage forms subject to the chapter
• §2 Personnel Training and Evaluation — initial + every-12-months core competency
• §7 Master Formulation and Compounding Records — required MFR and CR content
• §10.3 Establishing a BUD for a CNSP / Table 4 — water-activity (a_w) framework; 14 / 35 / 90 / 180-day ceilings
• §12 Quality Assurance and Quality Control — required QA/QC program elements; annual review

USP 〈797〉 Pharmaceutical Compounding — Sterile Preparations (official as of February 1, 2025)

• §1.5 CSP Categories — Category 1, 2, 3 framework
• §4 Facilities and Engineering Controls — ISO 5/7/8 cleanroom suite vs. unclassified SCA for Cat 1
• §12.2 Sterility Testing — when required for Category 2/3
• §14.3 / Tables 12, 13, 14 — BUD ceilings by category, process, and sterility testing status
• §14.4 Additional Requirements for Category 3 CSPs — sterility testing every batch; stability data; quarterly personnel competency

USP 〈800〉 Hazardous Drugs — Handling in Healthcare Settings

• §2 List of Hazardous Drugs — NIOSH list; assessment of risk for select dosage forms
• §5.3 Compounding — C-PEC inside C-SEC requirements for sterile and non-sterile HD compounding; ACPH and pressure differentials
• §7 Personal Protective Equipment — two pairs ASTM D6978 chemotherapy gloves; permeation-resistant gown
• §8 Hazard Communication Program — written acknowledgment of risk by personnel of reproductive capability
• §12 Dispensing Final Dosage Forms — exception for counting/repackaging intact final dosage forms
• §15 Deactivation, Decontamination, Cleaning, and Disinfecting — distinct steps; defined agents
• §18 Medical Surveillance — baseline + ongoing surveillance program

Official text and current revision status are maintained at uspnf.com. This article is practical guidance, not legal or regulatory advice — consult your State Board of Pharmacy and qualified counsel for compliance determinations specific to your operations.